Barcelona, September 5th, 2023
Solid Technologies SL (aka ‘Solitek’), a pioneering pharmaceutical and preclinical formulation development company, is thrilled to announce the establishment of its distinguished Advisory Board. Comprised of seasoned industry leaders, this esteemed panel of experts will bolster Solitek’s commitment to advancing pharmaceutical solutions and driving innovation in the field of preclinical development.
The formation of the Advisory Board marks a significant milestone for Solitek, signaling the company’s dedication to enhancing its capabilities, staying at the forefront of the pharmaceutical sector, and ensuring excellence in its product offerings.
Two Highly Accomplished Advisors Join Solitek’s Advisory Board:
Dr. Sudhakar Garad – With an illustrious career spanning over three decades, Sudhakar Garad, currently Global Head of Chemical and Pharmaceutical Profiling at NIBR, is a recognized figure in the pharmaceutical industry. He has held key leadership positions in various global pharmaceutical companies, contributing to the successful development of numerous drugs. Dr. Garad’s expertise in research and development, novel drug delivery, and on the impact of physicochemical properties on absorption (biopharmaceuticals) will be invaluable in guiding Solitek’s strategic decisions.
Dr. Michael J. Wilkins – Michael J. Wilkins, currently a pharmaceutical consultant, after retiring from his position as Head of Pharmaceutical Formulation Development at Almac Pharma Services, brings a wealth of experience and expertise to Solitek’s Advisory Board. With a distinguished career in preclinical, clinical and commercial formulation development, Dr. Wilkins has played an instrumental role in advancing cutting-edge drug delivery systems. His profound knowledge of drug formulation technologies and industry trends will empower Solid Technologies SL to create innovative and efficient pharmaceutical solutions.
Together, Dr. Garad and Dr. Wilkins will work closely with Solitek’s leadership team, providing invaluable insights, strategic guidance, and mentorship to further the company’s mission of delivering high-quality pharmaceutical and preclinical formulations products to the global healthcare market.
“We are extremely delighted to welcome Sudhakar and Michael to our Advisory Board,” said Victor Diaz, Operations Director and founder of Solitek. “Their exceptional expertise and accomplishments in the pharmaceutical sector will undoubtedly strengthen our position in the industry and accelerate our efforts in developing groundbreaking solutions for the benefit of patients worldwide.”
The combined experience of the newly appointed advisors will complement the existing strengths of Solitek’s dedicated team of scientists, researchers, and professionals. With a shared vision for pushing the boundaries of pharmaceutical innovation, the Advisory Board will foster an environment of collaboration and excellence.
About Solid Technologies SL:
Solid Technologies SL is a dynamic pharmaceutical services company committed to revolutionizing drug development and preclinical formulation. Driven by a passion for scientific innovation, Solitek strives to improve patient outcomes by delivering safe, effective, and high-quality pharmaceutical products. With state-of-the-art facilities and a team of top-tier experts, Solitek is well-positioned to lead the way in the ever-evolving pharmaceutical landscape.
For more information about Solid Technologies SL, please visit
www.solitekpharma.com or www.linkedin.com/company/solitekpharma/.
Victor M. Diaz
Solid Technologies SL (‘Solitek’)